Dealing with cancer can be difficult for all concerned. Here we have provided numerous resources of dedicated advice provided by patients, for patients.
FMD vaccines with highly potent and purified antigens (Aftopor®, Aftovaxpur®, Aftobov® Oleosa) allow differentiation between infected and vaccinated animals for endemic or emergency situations.
The pyramid®/presponse® family of vaccines provides broad coverage for BVD types 1 and 2, IBR, BRSV, PI3 and Mannheimia haemolytica with only a single dose.
For active immunisation of pigs from the age of three weeks against intestinal lesions caused by Lawsonia intracellularis infection and to reduce growth variability and weight loss associated with the disease.
Boehringer Ingelheim developed the only licensed blood clot dissolving treatment (thrombolytic) for acute ischaemic stroke therapy, now used worldwide.
Active immunisation of sheep to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotypes 1, 2, 4 and/or 8 (combination of maximum 2 serotypes).
At Boehringer Ingelheim we're improving treatments for patients suffering from a range of cardiovascular conditions atrial fibrillation, stroke & blood clots.
At Boehringer Ingelheim we are dedicated to working on improving treatments for cancer patients everywhere with a focus on lung and gastrointestinal cancers.
Click to discover the importance of clinical studies for developing new medicines & see some of the clinical trials Boehringer Ingelheim have sponsored.
Na Boehringer Ingelheim, o nosso pilar More Green, do nosso compromisso "Desenvolvimento Sustentável ao longo de Gerações", é um programa de longo prazo que engloba uma série de actividades implementadas há mais de uma década.